Drug Trial Radar · NCT02813135
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
472
Planned (sponsor's estimate)
Start
Aug 3, 2016
Primary completion
Feb 2031
Study completion Feb 2031
Sponsor
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute, France; Fight Kids Cancer; Fondation ARC
- First posted
- Jun 24, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This proof-of-concept platform trial is designed to cover the targeting of several survival pathways in oncogenesis that are currently not adequately employed for pediatric patients in Europe (Geoerger 2017; Geoerger 2019). The aims of the trial are: 1. To determine the recommended phase II dose (RP2D) of a specific anticancer agent and/or a relevant combination in a pediatric population, to document its tolerability and 2. To explore first signals of activity in a molecularly enriched study population.
Conditions
- Pediatric Cancer
Interventions
RibociclibDrug
TopotecanDrug
TemozolomideDrug
EverolimusDrug
AdavosertibDrug
CarboplatinDrug
OlaparibDrug
IrinotecanDrug
VistusertibDrug
NivolumabDrug
CyclophosphamideDrug
SelumetinibDrug
EnasidenibDrug
LirilumabDrug
FadraciclibDrug
CytarabineDrug
DexamethasoneDrug
CeralasertibDrug
FutibatinibDrug
CapmatinibDrug
AvelumabDrug
PeposertibDrug
CapivasertibDrug
VinorelbineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended phase II dose (RP2D)Time frame: During the first cycle
- Maximum Tolerated Dose (MTD)Time frame: During the first cycle
- Objective Response Rate (ORR)Time frame: During treatment period
Locations
23 sites in 6 countries. Site status is shown where the registry gives one.
Rigshospitalet
Copenhagen, Denmark · Recruiting
CHU Angers
Angers, France · Recruiting
CHU Pellegrin
Bordeaux, France · Recruiting
Centre Oscar Lambret
Lille, France · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
Hôpital de La Timone
Marseille, France · Recruiting
CHU Nantes
Nantes, France · Recruiting
Institut Curie
Paris, France · Recruiting
Hôpital Armand Trousseau
Paris, France · Recruiting
Hôpital de Hautepierre
Strasbourg, France · Recruiting
Gustave Roussy
Villejuif, Val de Marne, France · Recruiting
Istituto Giannina Gaslini
Genova, Italy · Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy · Recruiting
Ospedale Infantile Regina Margherita
Torino, Italy · Recruiting
Prinses Maxima Centrum
Utrecht, Netherlands · Active not recruiting
Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital del Nino Jesus
Madrid, Spain · Recruiting
Hospital Universitario La Fe
Valencia, Spain · Recruiting
Birmingham Children's Hospital
Birmingham, United Kingdom · Recruiting
Great Ormond Street Hospital
London, United Kingdom · Recruiting
Royal Manchester Children's Hospital
Manchester, United Kingdom · Recruiting
Royal Victoria Infirmary
Newcastle, United Kingdom · Recruiting
Pediatric and Adolescent Oncology The Royal Marsden Hospital
Sutton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.